A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Allogeneic-adipose-derived-mesenchymal-stem-cell-therapy-AbelZeta-Pharma (Primary) ; Hyaluronic acid (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
Most Recent Events
- 19 Mar 2025 Planned number of patients changed from 488 to 520.
- 19 Mar 2025 Status changed from not yet recruiting to recruiting.
- 28 Aug 2024 New trial record